Get the Stockscreener App
0.166
2.58%
-0.0044
Pre-market:
.17
0.004
+2.41%
Glycomimetics Inc stock is traded at $0.166, with a volume of 1.76M.
It is down -2.58% in the last 24 hours and down -30.89% over the past month.
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
See More
Previous Close:
$0.1704
Open:
$0.1791
24h Volume:
1.76M
Relative Volume:
1.72
Market Cap:
$13.55M
Revenue:
$1.16M
Net Income/Loss:
$-39.74M
P/E Ratio:
-0.2677
EPS:
-0.62
Net Cash Flow:
$-35.02M
1W Performance:
-20.95%
1M Performance:
-30.89%
6M Performance:
-40.80%
1Y Performance:
-37.73%
1-Day Range:
$0.16
$0.1791
1-Week Range:
$0.1515
$0.2118
52-Week Range:
$0.1406
$0.63
Glycomimetics Inc Stock (GLYC) Company Profile
Name
Glycomimetics Inc
Sector
Industry
Phone
240-243-1201
Address
9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Compare GLYC with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLYC
Glycomimetics Inc
|
0.166 | 13.55M | 1.16M | -39.74M | -35.02M | -0.62 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.44 | 114.49B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
518.60 | 52.36B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
298.58 | 39.81B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
574.96 | 35.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
262.41 | 27.94B | 3.81B | -644.79M | -669.77M | -6.24 |
Glycomimetics Inc Stock (GLYC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-21-25 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-22-23 | Initiated | CapitalOne | Overweight |
| Nov-12-21 | Upgrade | Jefferies | Hold → Buy |
| Nov-14-19 | Initiated | ROTH Capital | Buy |
| Aug-05-19 | Downgrade | Jefferies | Buy → Hold |
| Aug-05-19 | Downgrade | Piper Jaffray | Overweight → Neutral |
| Aug-05-19 | Downgrade | SunTrust | Buy → Hold |
| Apr-12-19 | Initiated | Piper Jaffray | Overweight |
| Dec-18-18 | Initiated | H.C. Wainwright | Buy |
| Jul-26-16 | Initiated | SunTrust | Buy |
| Mar-17-15 | Reiterated | Stifel | Buy |
View All
Glycomimetics Inc Stock (GLYC) Latest News
Cantor Fitzgerald Comments on GlycoMimetics FY2026 Earnings - Defense World
GlycoMimetics (NASDAQ:GLYC) Shares to Reverse Split on Monday, June 16th - Defense World
Where Do Analysts Think The GlycoMimetics Inc (NASDAQ: GLYC) Is Going - Stocksregister
Wellington Management Group LLP Takes Position in GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
GlycoMimetics Stockholders Approve Merger with Crescent Biopharma - TipRanks
GlycoMimetics Stockholders Approve Proposed Merger With Crescent Biopharma And All Related Proposals - marketscreener.com
GlycoMimetics Stockholders Approve Merger with Crescent Biopharma and All Related Proposals - citybiz
GlycoMimetics (GLYC) Stockholders Approve Merger with Crescent Biopharma | GLYC Stock News - GuruFocus
GlycoMimetics announces 1-for-100 reverse stock split - Investing.com Australia
GlycoMimetics announces 1-for-100 reverse stock split By Investing.com - Investing.com Canada
GlycoMimetics stockholders approve proposed Crescent Biopharma merger - TipRanks
GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals - Business Wire
GlycoMimetics Announces Merger Amidst Uncertainties - TipRanks
Crescent Biopharma to Present at the Jefferies Global Healthcare Conference - The Manila Times
GlycoMimetics executives to depart amid merger plans - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RDFN, LRFC, RDW, GLYC on Behalf of Shareholders - TradingView
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NDOI, SSBK, BRDG on Behalf of Shareholders - GlobeNewswire Inc.
GlycoMimetics (NASDAQ:GLYC) Now Covered by Analysts at StockNews.com - Defense World
GlycoMimetics (NASDAQ:GLYC) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell? - Defense World
GlycoMimetics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc.GLYC - marketscreener.com
GlycoMimetics: Q1 Earnings Snapshot - CT Insider
GLYCOMIMETICS INC SEC 10-Q Report - TradingView
StockNews.com Begins Coverage on GlycoMimetics (NASDAQ:GLYC) - Defense World
GlycoMimetics, Inc. to Host Earnings Call - ACCESS Newswire
$TOCKHOLDER ALERT: The M&A Class Action Firm Continues Its Investigation Into The MergerGLYC, BRZH, PRA, FVNNU - The Malaysian Reserve
$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – GLYC, BRZH, PRA, FVNNU - TradingView
GLYCGlycomimetics Latest Stock News & Market Updates - Stock Titan
A Stock Analysis Of GlycoMimetics Inc’s (GLYC) - Stocksregister
GlycoMimetics (NASDAQ:GLYC) Coverage Initiated at StockNews.com - Defense World
Ratios Revealed: Decoding GlycoMimetics Inc (GLYC)’s Financial Health - DWinneX
GlycoMimetics Inc (GLYC Stock: A Sea of Opportunity - investchronicle.com
Cantor Fitzgerald initates GlycoMimetics Inc (GLYC) rating to an Overweight - knoxdaily.com
GlycoMimetics Amends Merger Agreement With Crescent Biopharma - Investing.com
GlycoMimetics, Inc. (GLYC) Stock Report: Analyst Ratings Signal Potential in Biotech Space - DirectorsTalk Interviews
Press Release Distribution & PR Platform - ACCESS Newswire
A Look at GlycoMimetics Inc (GLYC) Shares in the Recent Past Indicates Growth - Sete News
GLYC Shares Experience Surge in Value - knoxdaily.com
GlycoMimetics (NASDAQ:GLYC) Stock Price Passes Below 200 Day Moving Average – Time to Sell? - Defense World
GlycoMimetics Inc (GLYC) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Understanding GLYC stock ratios for better investment decisions - uspostnews.com
GlycoMimetics (NASDAQ:GLYC) Now Covered by StockNews.com - Defense World
Wellington Management Group LLP Makes New Investment in GlycoMimetics, Inc. (NASDAQ:GLYC) - Defense World
Glycomimetics Inc Stock (GLYC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.92%
7.75%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):